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Background: Adherence to inhaled corticosteroids (ICS) remains poor among asthmatics, yet
little is known about the efficacy of interventions to improve adherence. Implementing the
Chronic Care Model (CCM) components among patients with respiratory disorders has been
associated with an improvement in outcomes, yet little is known about its effects on ICS adher-
ence in asthmatics.
Objective: We conducted a systematic review to assess the efficacy of interventions to
improve ICS adherence among adult-asthmatics, and whether the use of CCM components
(i.e., teaching self-management skills, providing decision support, delivery system design,
and clinical information systems) resulted in greater ICS adherence.
Methods: All English language articles testing the efficacy of an intervention including ICS
medication on outcome from MEDLINE and PsychINFO databases through Aug-2010 were re-
viewed. Interventions were categorized based on the inclusion of CCM components. We stan-
dardized treatment effects to obtain effect-size’s (ES’s) and we combined the ES’s of studies
according to the number of CCM components included in their interventions.havioural Medicine Centre, Department of Psychology, University of Quebec at Montreal (UQAM), P.O.
ntreal, Quebec H3C 3P8, Canada. Tel.: þ1 514 987 3000x3835; fax: þ1 514 987 7953.
s.qc.ca (K.L. Lavoie).
o first authorship of the manuscript.
2 Elsevier Ltd. All rights reserved.
2.06.001
1212 G. Moullec et al.Results: Eighteen studies met inclusion criteria. Inclusion of a greater number of CCM compo-
nents within interventions was associated with stronger effects on ICS adherence outcomes,
with interventions featuring one, two, and four CCM components having medium
(ES Z 0.29; 95%CI, 0.16e0.42), large (0.53; 0.40e0.66), and very-large (0.83; 0.69e0.98)
effects respectively.
Conclusions: Findings provide support for using the CCM as a framework for the design and im-
plementation of interventions to improve adherence among adult-asthmatics.
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Asthma is a chronic disorder characterized by reversible
and intermittent airway obstruction, airway inflammation,
and hyper-reactivity of the airways in response to a variety
of stimuli (e.g., pollen, dust, pets, smoke, exercise, and
emotions).1 Although important advances in pharmacolog-
ical treatment and diagnosis have occurred over the past
years, 300 million people worldwide suffer from asthma,
making this condition one of the most frequent chronic
diseases in the world.2,3 Poorly controlled asthma patients
are more likely to experience further exacerbations,
a poorer quality of life, and require greater medical
attention compared to well-controlled patients, therefore
placing a higher burden on the health care system.4e6
According to recent Canadian statistics, less than 42% of
asthma patients have adequately controlled asthma.7
There are several options to optimize asthma control
including daily peak expiratory flow (PEF) monitoring,action plans in the event of symptom exacerbation, mini-
mizing exposure to known asthma triggers (e.g., indoor
allergens, pollution, smoke), and daily adherence to
controller medication (i.e., inhaled corticosteroids,
ICS).5,6,8 Among these strategies, daily adherence to ICS is
considered to be one of the most important strategies to
improve control of asthma symptoms.6,8e16 However, an
estimated 60%e80% of patients do not take their ICS regi-
mens as prescribed (i.e., patients take less than 75% of
their ICS prescriptions more than 80% of the time),9,11,17e20
including patients suffering from severe asthma19,21 who
would most benefit from this treatment.8,22
Over the past 20 years, researchers have focused on
designing behavioral interventions to enhance controller
(i.e., ICS) adherence among adult asthmatics.23 However,
the vast majority did not provide any theoretical rationale
for the development of their intervention.24 One recom-
mended method25,26 for exploring mechanisms for positive
change associated with behavioral interventions, is to
Improve adherence to ICS in adult asthmatics 1213evaluate intervention components quantitatively e within
a theoretical framework. Wagner’s Chronic Care Model
(CCM) is a well-known framework aimed at improving the
care of patients with chronic diseases. The CCM integrates
a number of elements into a model designed to encourage
more productive interactions between healthcare teams
and patients.27 Previous systematic reviews have shown
that implementing the CCM components in patients with
asthma28,29 and other respiratory diseases such as chronic
obstructive pulmonary disease (COPD)29,30 has been asso-
ciated with significantly improved outcomes (e.g., quality
of life, exercise tolerance, control of symptoms). However,
little is known about the specific effects of implementing
this model on ICS adherence in asthmatic patients.
We conducted a systematic review and meta-analysis to
better understand the strengths and limitations of tested
interventions for improving ICS use among adult asthma
patients, with the goal of identifying those that are more
likely to be efficacious. We examined whether interven-
tions with a greater number of CCM components predicted
better adherence outcomes among adult asthmatics
compared to interventions with fewer CCM components.
We report their relative impact using a standardized
measure of effect size, and discuss the clinical impacts and
implications for future research.Methods
Literature search
This review included all English-language peer-reviewed
articles from the following databases (via the Ovide portal):
MEDLINE (1948-August 2010, week 4) and PsychINFO (1967-
August 2010, week 4). Search terms were: “asthma or
asthmatics or adult asthma”, “intervention or trial or
program”, “medication adherence or treatment adherence
or treatment compliance”, “medication compliance or
corticosteroids adherence or corticosteroids compliance”.
We combined these terms by using the Boolean ‘AND’
operator. We further complemented this search byTable 1 Interventions categorized into the components of the
CCM components Interventions
Self-management (SM) - Education (promote p
teach specific prevent
- Behavioral support (p
self-monitoring, e.g.,
- Motivational (linking s
Decision support (DS) - Use of evidence-based
- Integrate specialty ex
- Use of theory-driven e
Delivery system design (DSD) - Use of case managers
- Multidisciplinary team
preventative measure
- Scheduling of planned
Clinical information system (CIS) - Clinical registries (dat
- Provide timely remind
- Share information witreviewing the reference sections of the identified articles
and reviews, and by consulting experts in the field.
Study selection and data extraction
Two reviewers (G.G.P. and K.L.L.) independently selected
studies for inclusion with the following criteria: (1) it had to
test the efficacy or effectiveness of an intervention that
included asthma controller medication (i.e., ICS) as one of
its outcomes; (2) it had to focus on adult populations
(studies focusing on pediatric or adolescent populations
were excluded as adherence behavior in children is often
dependent on their parent’s attitudes and behavior)31,32;
and (3) in studies that included combined disease pop-
ulations (e.g. asthma and COPD), results had to have been
presented separately for asthmatics. If an article was
selected by either reviewer, it was included in full-text
review and evaluated by both reviewers. Two reviewers
(G.G.P. and G.M.) independently extracted data on a stan-
dardized abstraction form created for this study. Inter-
ventions were categorized based on the number of CCM
components they included. These components included
teaching self-management skills, providing decision
support, delivery system design, and clinical information
systems (see descriptions in Table 1). The remaining CCM
components, i.e., ‘healthcare organization’ and ‘commu-
nity resources’ (see www.improvingchroniccare.org), were
not included in the studies selected in the current review
and as such were not included in this study. The quality of
selected studies was assessed using the Downs and Black’s
checklist.33 Studies were assigned a quality ranking based
on their final score: high, 16; moderate, 8e16; low, <8.
Data synthesis
Adherence measures were expressed across studies with
different units; we therefore standardized the resulting
treatmenteffects (i.e., change inadherence level) toobtainan
effect size (i.e., ES e standard mean difference). So, when
possible, the ES for the intervention with its 95% confidence
interval (CI) was calculated from the information provided inCCM.
atients’ understanding of their respiratory condition and
ion and treatment strategies)
roviding tools to modify behaviours and optimize
peak flow)
pecific goals for behavioural changes to clinical information)
guidelines to help decision-making
pertise (e.g., referrals for management of co-morbidities)
ducation program
, structured telephone follow-up
s (increased involvement of pharmacists) to coordinate
s for chronic care
asthma follow-up visits
abases available for all providers)
ers for providers and patients
h patients and providers
Figure 1 Selection process for including studies in system-
atic review and meta-analyses. Notes: Reasons: 1Z didn’t test
the efficacy or effectiveness of an intervention that included
asthma controller medication; 2 Z pediatric or adolescent
populations; 3 Z combined disease populations; 4 Z non-
English.
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analyses were performed, as recommended by Wilson and
Lipsey,34 by pooling the ES’s of studies according to the number
of CCM components included in their interventions. For studies
that provided ranges instead of standard deviations, we con-
verted ranges to standard deviations according to the method
described by Walter et al. (2007).35 If authors did not specify
the number of patients included in the final analyses, we used
the baseline sample size of each group to calculate the ES. The
inconsistency of effects between study findings was measured
by using the I2 statistic as proposed by Higgins et al.36 The
absolute value of each statistically significant ES was catego-
rized as small (<0.20), medium (0.20 to<0.50), large (0.50 to
<0.80), or very large (0.80).37 Beyond the standard inter-
pretation (very large in size), anESequal to0.80would indicate
that the intervention groupmean is 0.8 of a standard deviation
above the control group mean.
Results
The literature search yielded a total of 188 references, the
titles and abstracts of which were reviewed for study
content and relevance and all duplicates and reviews were
removed. A final sample of 18 studies38e52 met inclusion
criteria and were included in this review (see Fig. 1 as per
the PRISMA statement).53
Study designs
All 18 studies included in this review employed a random-
ized control trial (RCT) design. Table 2 summarizes study
population characteristics, intervention characteristics,
and type of adherence measures used. Among the included
studies, 1038e47 involved interventions that included one
CCM component (with different combinations of sub-
components under self-management support, i.e., educa-
tion, behavior therapy, motivational interviewing); seven
studies38,40,48e52 included two CCM components, and two
studies54,55 included four CCM components.
Patient characteristics
All but one study (94%) was conducted among moderate to
severe asthma patients.38e41,43e52 One was conducted
among both moderate-severe asthmatics and COPD outpa-
tients.42 The average sample size across studies was 167
patients (range Z 25e612). Among studies that reported
patient age (14/18, 78%), participants ranged in age from
35 to 50 years. Women were somewhat over-represented in
most studies, with participation rates ranging from
52%47e73%.50 Participant retention rates over the follow-up
periods ranged from 74%51e98%.41
Intervention characteristics
A summary of intervention characteristics can be found in
Table 2. Overall, interventions were quite heterogeneous.
We categorized the interventions based on the number of
CCM components they included. All studies included a self-
management component (i.e., education, and/or behaviortherapy and/or motivational interviewing). Most studies
(i.e., 14/18, 78%) conducted individual inter-
ventions,38,39,41,43e47,49e51 and four studies conducted both
individual and group interventions.40,42,48,52 The duration of
the intervention varied greatly across studies and ranged
from a single 30 min session56 to more than 12 h41
(mean Z 3 h; median Z 2 h). In addition, follow-up
length ranged from 1 week41 to 2 years40,55 (mean Z 10
months; median Z 9 months). In order to increase the
homogeneity between studies included in our quantitative
analyses, for studies with follow-ups longer than 12 months,
we analysed 12 month data.Adherence measures
Measuresofadherencealso variedgreatly across studies.Most
studies (i.e, 7/18, 39%) measured adherence using self-
reports. Five studies (28%) measured adherence according
to pharmacy refill rates, with patients being considered
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least 80%of the time.38,42,49,51,56 Fivestudies (28%)40,43,47,48,52
measured adherence according to scores on validated self-
report questionnaires such as the Morisky Questionnaire and
the Adherence Scale, which have good psychometric proper-
ties.57,58 One study45 measured adherence by conducting an
audit of general practitioner records,48 three used an elec-
tronic monitoring device,41,44,54 three weighed inhaler
canisters,18,39,55 and one used a dose counter.50 Most studies
(i.e., 11/18, 61%) included a single measure of
adherence,18,38e40,42,44e46,49,50,52 and seven included two
measures.41,43,47,48,51,55,56
Efficacy of interventions
Among the 14 studies (78%)38,40e48,50e52,54e56 for which
a standardized ES for adherence outcomes could be calcu-
lated (see Fig. 2), the efficacy of the interventions according
to the number of CCM components they included was
assessed. Interestingly, of the thirteen studies that evalu-
ated the efficacy of one CCM component (teaching self-
management skills38,40e47,56 or decision support40) only
three (23%)41,42,47 were associated with significant ES’s
(0.52e0.57). Of the five studies incorporating two CCM
components, i.e., teaching self-management skills and
delivery system design48,50,52/or decision support,38,51 two
(40%) had a large ES’s (0.60 and 0.62)48,52 and the remainder
had medium ES’s (0.43 for both)50,51 though one had no
effect.38 Finally, two54,55 of the three (66%)55 studies where
usual care was compared with a program including four CCM
components were associated with the highest (i.e. very
large) ES’s (0.91 and 1.12). When we combined the ES’s of
studies according to the number of CCM components
included in their interventions (i.e., one, two, four), we
observed a pooled ES of 0.29 (95%CI, 0.16e0.42), 0.53
(0.40e0.66) and 0.83 (0.69e0.98) respectively.
Discussion
Main results
The purpose of this reviewwas to evaluatewhether the use of
CCM-based intervention components resulted in greater ICS
adherence outcomes among adult asthma patients partici-
pating in RCT’s designed to directly or indirectly improve ICS
adherence. As expected, the inclusion of a greater number of
CCM components within interventions was associated with
stronger effects on ICS adherence outcomes. Interventions
featuringone, twoand fourCCMcomponentshad respectively
medium, large, and very large effect sizes. These findings
provide support for the use of the CCM as a framework for the
design and implementation of interventions that improve
adherence outcomes among adult asthmatics.
Importance of using a theoretical framework for
intervention design
Despite the fact that heterogeneity exists in the content
and methodological features (e.g., adherence measure
used; length of follow-up) of the interventions, we noted
that trials incorporating a greater number of CCMcomponents had a greater effect on ICS adherence. This
raises questions about what components of the CCM are
responsible for the efficacy seen in asthmatic patients. It’s
difficult to respond with certainty insofar as few data exist
highlighting the causal processes that underlie the
programs’ efficacy. However, we could speculate on how
and why these findings were observed. To increase the
readibility of the paragraph, it may be useful to create
a subsection here. A recent Dutch conceptual framework
derived from Program Theory59 offers an interesting model
for understanding how complicated interventions within
the context of chronic disease management affect
outcomes of care. The authors delineate mechanisms of
change according to the target level or focus of the inter-
vention, i.e., whether it is patient-centred, health-care-
centred, and/or organisational-centred. According to this
model,60 programs targeting healthcare providers is crucial
for changing the partnership dynamic between patients and
providers, and ultimately, patient behavior change. Access
to decision support should affect provider behavioral
intention, which in turn, influences provider behavior and
may lead to improved patient health outcomes. When
informed, patients take an active role in managing their
health, and providers feel prepared and supported when
they have access to appropriate resources. This may render
their mutual interactions more productive. Therefore,
when both patients and providers are targeted, collabora-
tive management is more likely, leading to a sustained
working relationship and mutual understanding of roles and
responsibilities. However, this synergy is possible only if it is
supported by a third element, the organisational design of
the healthcare system (i.e., delivery system design,
healthcare organization and community). Thus, according
to this model, three simultaneous causal pathways are all
required for a behavioral intervention to succeed, as they
all appear to be essential for changing patient health
behaviours (such as ICS adherence). The results of this
review appear, in part, to support this framework. Further
research is needed to test this kind of model and refine our
understanding of the mechanisms explaining the synergistic
effects of such three-tiered interventions.Importance of using an appropriate intervention
development process
Our ability to improve health-related behaviors, such as ICS
adherence, is dependent on increasing our understanding
of the fundamental bases of human behaviour and trans-
lating that knowledge into well-defined, effective inter-
ventions.26,61 In drug development, research on the
development, testing and refining of interventions is
labelled “bench to bedside” or Translation I research.
Translational I research begins with basic biological
research to identify mechanisms and intervention targets,
which then proceeds to small-scale human trials to assess
safety and optimal dosing, and often includes pilot studies
to assess feasibility and estimates of effect size. These
early phases of drug development are followed by larger-
scale, Phase III clinical trials that test the efficacy and
effectiveness of the treatment on the health outcomes of
interest in clinical practice and community settings. This
Table 2 Summary of reviews.
Study Location Study
design
Study
quality
Mean
age,
y (I/C)
% Male
(I/C)
Interventions Duration
individual /
Group
Length of
follow-up
Adherence
measures
ES (95%CI) for
adherence
No. Enrolled or
randomized
No.
Completed
I C I C
Self-Management (Education or Behavioural Support)
Coˆte´ et al,
200138
Canada RCT
Moderate
35/38 33/46 I: SM (Behavioural
support)
C: UC
NA Individual 12 mo Prescription for
steroid inhaler (self-
reported)
None 0.25
(0.24e0.74)
NA 45 30 35
Schaffer
and Tian,
200456
United
States
RCT
Moderate
NA NA I: SM [Patient education:
(a)
audiotape
(b) or booklet
(c) or
audiotape þ booklet]
C: UC
30 min1 h
Individual
6 mo 1) % of Prescribed
doses (refill
audit)
2) % of Missed
doses (self-
reported)
1) (a) None, 0.16
(0.66e0.99)
(b) None, 0.81
(0.01e1.62)
(c) None, 0.80
(0.03e1.64)
2) NA
10
12
11
13 NA NA
Self-Management (Education D Behavioural Support [or Motivational])
Berg et al,
199741
United
States
RCT
Moderate
47/52 32/38 I: SM [Patient
education þ Behavioural
support (action plan based
on peak flow monitoring)]
C: UC
12 h Individual 1 wk (1) % of prescribed
ICS doses taken
(electronic
monitoring)
(2) Frequency of
inhaler use
(diary e self-
reported)
(1) Large 0.57
(0.03e1.12)
(2) NA
31 24 30 24
Couturaud
et al,
200243
France RCT
Moderate
38/38 31/33 I: SM [Patient
education þ Behavioural
support (action plan based
on peak flow and
symptoms monitoring)]
C: UC
2 h 30e5 h
Individual
12 mo (1) % of days oral
corticosteroid
use (self-
report)
(2) Self-reported
adherence to
inhaler (all 6
items eMorisky
scale)
(1) None 0.15
(0.39e0.68)
(2) NA
36 36 26 28
Coˆte´ et al,
199739
Canada RCT
Moderate
37/36 44/30 I: SM [Patient education
(1 h one-to-one session,
book) þ Behavioural
support (action plan based
on peak flow monitoring)]
C: UC
z3 h Individual 12 mo > 60% of prescribed
doses taken (weight
of used canisters)
NA* NA NA 50 54
Coˆte´ et al,
199739
Canada RCT
Moderate
39/36 33/30 I: SM [Patient education
(1 h one-to-one session,
book) þ Behavioural
z3 h Individual 12 mo > 60% of Prescribed
doses taken (weight
of used canisters)
NA* NA NA 45 54
1216
G
.
M
o
u
lle
c
e
t
a
l.
Support (action plan based
on symptoms)]
C: UC
Gallefoss
and Bakke,
199942
Norway RCT Good 41/44 38/21 I: SM [Patient education
(brochure, 40e80 min one-
to-one session, 2*2 h group
session) þ Behavioural
support (action plan based
on peak flow and
symptoms monitoring)]
C: UC
z5 h Individual
& Group
12 mo >75% of prescribed
doses of inhaled
steroid (refill audit)
Large, 0.52
(0.05e1.00)
39 39 32 39
Janson
et al,
200944
United
States
RCT
Moderate
37/40 47/46 I: SM [Patient education
(3*30 min individual
session) þ (action plan
based on peak flow and
symptoms monitoring)]
C: UC
1 h 30 Individual 6 mo % of prescribed ICS
doses taken
(electronic
monitoring)
None, 0.09
(0.34e0.52)
45 39 35 30
Levy et al,
200045
UK RCT Good 43/40 33/43 I: SM [Patient education
(3*30 min individual
sessions) þ Behavioural
support (action plan based
on peak flow and
symptoms monitoring)]
C: UC
2 h Individual 6 mo Increased use of
inhalers for asthma
attacks (self-
reported):
(1) for mild
attacks;
(2) for severe
attacks
(1) None, 0.51
(0.17e1.23)
(2) Large, 0.66
(0.30e0.98)
103 108 86 95
Morice and
Wrench,
200146
UK RCT
Moderate
NA 38/33 I: SM [Patient education
(3*30 min individual
sessions þ booklet þ ) þ
Behavioural support
(action plan based on peak
flow and symptoms
monitoring)]
C: UC
z1 h30 Individual 6 mo Frequency of
inhaler use (self-
reported)
None 0.44
(0.05e0.93)
40 40 35 30
Self-Management (Education D Behavioural D Motivational support)
Put et al,
200347
Belgium RCT
Moderate
43/48 58/38 I: SM [Patient education
(work book, home work
assignments) þ
Behavioural support (self-
monitoring, stimulus
control, response control)
þ Motivational support
(cognitive restructuring)]
C: UC
6 h Individual 6 mo Adherence Scale (1)
self-report, 3 mo
(2) self-report,
6 mo
(1) Large 0.75
(0.23e1.02)
(2) Large 0.52
(0.01e1.03)
13 12 12 11
(continued on next page)
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Table 2 (continued)
Study Location Study
design
Study
quality
Mean
age,
y (I/C)
% Male
(I/C)
Interventions Duration
individual /
Group
Length of
follow-up
Adherence
measures
ES (95%CI) for
adherence
No. Enrolled or
randomized
No.
Completed
I C I C
Self-Management D Decision Support
Coˆte´ et al,
200138
Canada RCT
Moderate
34/38 33/46 I: SM [Patient
education þ Behavioural
support (action plan based
on peak flow
monitoring)] þ DS
(interaction providers/
patients based on theory
of Bandura)
C: UC
z2 h 12 mo Prescription for
steroid inhaler (self-
reported)
None 0.44
(0.04 to0.92)
NA 45 33 35
Mehuys et al.,
200851
Belgium RCT Good 36/35 46/48 I: SM [Patient
education þ Behavioural
support (peak flow
monitoring)] þ DS
(pharmacists education on
GINA guidelines)
C: UC
NA 6 mo (1) % of prescribed
doses of inhaled
steroid (refill
audit e phar-
macy claims)
(2) Prescription for
steroid inhaler
(self-reported)
(1) Medium 0.43
(0.10e0.75)
(2) None 0.27
(0.05 to0.60)
107 94 80 70
Self-Management D Delivery system Design
Bailey et al,
199048
United
States
RCT Good NA 39/29 I: SM [Patient education
(1 h one-to-one
counselling session, work
book) þ Behavioural
support (peak flow
meter þ 2 group
meetings þ 3 follow-up
letters)] þ DSD
[structured telephone
support (2 calls)]
C: UC
z2 h30 Individual
& Group
12 mo (1) Self-reported
adherence to
inhaler (5 of 6
items eMorisky
scale)
(2) Self-reported
adherence to
inhaler
(all 6 items e
Morisky scale)
(3) Adherence to
inhaler (rated
by staff)
(1) Large, 0.72
(0.45e0.99);
(2) Large 0.62
(0.35e0.88)
(3) Medium, 0.60
(0.33e0.87)
132 135 124 101
Bailey et al,
199940
United
States
RCT Good NA 30/30 I: SM [Patient education
(1 h one-to-one
counselling session, work
book) þ Behavioural
support (peak flow
meter þ 2 group
z2 h30
Individual
& Group
24 mo Self-reported
adherence to
inhaler (all 6 items
eMorisky scale)
(1) (12 mo)
None, 0.05
(0.27e0.36)
78 78 NA NA
1218
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meetings þ 3 follow-up
letters)] þ DSD
[structured telephone
support (2 calls)]
C: SM [Patient education
(pamphlets)]
(2) (24 mo):
Medium, 0.40
(0.09e0.72)
Bailey et al,
199940
United
States
RCT Good NA 32/30 I: SM [Patient education
(15e20 min one-to-one
counselling session,
shortened work
book) þ Behavioural
support (action plan based
on peak flow
monitoring þ 1 follow-up
letter)] þ DSD [Structured
telephone support (1 call)]
C: SM [Patient education
(pamphlets)]
z30 min
Individual
24 mo (1) Self-reported
adherence to
inhaler (all 6
items eMorisky
scale)
(1) (12 mo)
None 0.00
(0.32
to 0.32)
(2) (24 mo):
None, 0.15
(0.16 to
0.47)
76 78 NA NA
Chatkin et al,
200650
Brazil RCT
Moderate
43/44 26/29 I: SM (Patient
education) þ DSD
[Structured telephone
support (6 calls)]
C: UC
1 h Individual 3 mo % of prescribed
doses taken (disk
records)
Medium 0.43
(0.24e0.72)
140 131 NA NA
DeLaronde
et al,
200549
United
States
RCT
Moderate
35/36 43/52 I: SM [Patient education
(educational booklet and
video)] þ DSD [structured
telephone support (6
calls)]
C: UC
z1 he1 h30
Individual
12 mo Ratio of number of
dispensed anti-
inflammatory drugs
on (dispensed b2
agonist þ anti-
inflammatory drugs)
(Pharmacy claims
data)
NA* 67 67 67 67
Windsor et al,
199052
United
States
RCT
Moderate
50/49 39/29 I: SM [Patient education
(30 min one-to-one
session) þ Behavioural
support (action plan based
on peak flow
monitoring þ 1 h group
session)] þ DSD
[Structured telephone
support (2 calls]
C: UC
z2 h Individual
& Group
12 mo Self-reported
adherence to
inhaler (all items
 Morisky scale)
Large 0.60
(0.34e0.88)
132 135 124 101
(continued on next page)
Im
p
ro
ve
a
d
h
e
re
n
ce
to
IC
S
in
a
d
u
lt
a
sth
m
a
tics
1219
Table 2 (continued)
Study Location Study
design
Study
quality
Mean
age,
y (I/C)
% Male
(I/C)
Interventions Duration
individual /
Group
Length of
follow-up
Adherence
measures
ES (95%CI) for
adherence
No. Enrolled or
randomized
No.
Completed
I C I C
Self-Management D Decision Support D Delivery system Design D Clinical Information System
Bender et al,
201054
United
States
RCT
Moderate
40/43 40/32 I: SM (Patient
education þ Behavioural
support) þ DS
(intervention based on the
benefit-risk model) þ DSD
[Structured telephone
support (2-3 calls þ Free
telephone service] þ CIS
(database with automatic
storage of all call
information)
C: UC
z 30e45 min
Individual
10 wks % inhaler puffs
prescribed
(electronic
monitoring or
weight of used
canisters)
Very large 0.91
(0.32e1.49)
25 25 25 25
Wilson et al.,
2010a55
United
States
RCT Good 46/45 44/43 I: SM [Patient
education þ Behavioural
support þ Motivational
support (e.g., barriers to
medication adherence
elicited and
addressed)] þ DS (All
managers trained
separately þ use of GINA
guidelines) þ DSD
[Structured telephone
support (3
calls) þ Scheduling of
follow-up appointment þ
Coordination between
care providers and
patient’s physicians] þ CIS
(Patient’s charts
documented by the case
managers and available to
the patient’s physician)
C: UC
z3 h Individual 24 mo (1) Continuous
medication
acquisition
index (refill
audit)
(2) ICS canister
equivalent
(weight of used
canisters)
(1) (12 mo):
Large 0.58
(0.38e0.77)
(2) (12 mo): Very
large 1.12
(0.91e1.33)
204 204 182 189
Wilson et al.,
2010b55
United
States
RCT Good 47/45 44/43 I: idem than above without
the motivational interview
C: UC
z2 h30 24 mo (1) Continuous
medication
acquisition
204 204 180 189
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Improve adherence to ICS in adult asthmatics 1221paradigm is well-accepted within the pharmaceutical
industry and has produced efficacious therapies. A similar
paradigm for behavioral medicine interventions has been
recently suggested by the National Institutes of Health
(NIH) in its innovative approaches to reduce obesity (i.e.,
Obesity-Related Behavioural Intervention Trials, program
ORBIT).61 This model provides a clear framework for
translating basic behavioural and social science discoveries
into efficacious behavioural interventions. The current
review that looks at better characterizing the key ingredi-
ents (i.e. including CCM components) of behavioural
interventions in asthmatic patients follows this essential
first step of the intervention development process. This
first step consists of providing a scientific basis for the
intervention, notably with a meta-analysis. The next step
will be to optimize the identified key CCM components,
notably in terms of dose/duration, mode of delivery,
acceptability, and cultural appropriateness. Only when
these important milestones are achieved will it be appro-
priate to move towards larger “Phase III and IV” trials
assessing efficacy and effectiveness.
Recommendations for future studies
Choice of adherence measure
The studies included in this review used several methods
for measuring adherence such as patient self-report diaries,
validated questionnaires, canister weighting, assessment of
prescription refills, and electronic monitoring. They vary in
cost, practicability, accuracy, complexity, and objectiv-
ity.62,63 Interestingly, in both studies51,55 where two
methods of assessing adherence were used and for which
a standardized ES could be calculated, the more objective
the measure of adherence (self-report vs. pharmacy
claims51 and pharmacy claims vs. canister weighting55), the
greater the ES’s. Therefore, the method of adherence
measurement is a potentially important moderator to take
into account when evaluating interventions that target ICS
adherence. More objective measures of adherence seem to
be more sensitive to capture changes following interven-
tion, with self-reports being the least sensitive (perhaps
due to reporting bias where patients have been shown to
overestimate their medication intake51,59), and pharmacy
refills and electronic devices (the latter of which provides
detailed records of time and date for every inhaler actua-
tion) being the most sensitive. This suggests that future
research would benefit from including more objective
methods of assessing adherence in order to improve diag-
nostic accuracy, optimize the likelihood of observing
meaningful differences in intervention effects, and to
inform treatment decisions.
Choice of comparison group
The choice of an appropriate comparison group is important
to judge the relative efficacy of an intervention under
study.64 If the aim of a trial is to determine whether a novel
intervention is superior to existing clinical practice, then it
has to be compared with those practices e knowing that
“usual” and “standard of” care changes over time. This may
Figure 2 Forest plot of studies. Notes: SM Z self-management; DS Z decision support; DSD Z delivery system design;
CIS Z clinical information system; I2 Z heterogeneity index (0e100%); * Z random effect model.
1222 G. Moullec et al.be why the two RCT’s by Bailey et al.,40,48 which despite
assessing the efficacy of the same intervention (i.e., self-
management education program þ structured telephone
follow-up), had very different ES’s (i.e., 0.62 and 0.05).Between 1990 when they published their initial study and
1999 when they published they second, usual or standard
clinical practice had changed and teaching asthma self-
management skills became routine. Therefore, in their
Improve adherence to ICS in adult asthmatics 1223second study, they only evaluated the added value of an
individualized structured telephone follow-up (i.e.,
considered as only one CCM element: delivery system
design) versus an education intervention alone. This
enhancement of usual care is likely to have explained the
disparate ES’s found for the same intervention across the
two studies.
Focus on key intervention ingredients
With many behavioral interventions including multiple
components, it is difficult to know which are more or less
important for changing the outcome of interest. However,
Wilson et al.’s55 study highlights the specific contribution of
one ingredient of the CCM for improving ICS adherence:
motivational support. This study included two groups; in
the first group, the choice of treatment was actively shared
and negotiated between the patient and the physician; in
the second group, the physician alone selected the treat-
ment regimen. The results showed that the shared-decision
making strategy was associated with a significant
improvement in ICS adherence compared to the physician-
only decision-making strategy (ES Z 0.25; 95%CI,
0.05e0.44). This finding from a well-powered RCT (i.e., 200
patients per arm) suggests the key role played by motiva-
tional support within the context of self-management
interventions, though more research is needed to confirm
this. Initiating and maintaining medication adherence
involves a complex series of behavioral changes. Behavior
change is most likely to occur when individuals are intrin-
sically motivated to engage in that behaviour and feel
confident in their ability to change65; two factors that are
rarely considered or targeted in asthma adherence inter-
ventions to date. Interventions that focus on improving
intrinsic motivation (which emphasizes engaging in
a behaviour because it is consistent with personal values,
such as having greater personal control over treatment
regimens), rather than extrinsic motivation (which
emphasized engaging in a behaviour to obtain external
rewards such as money or physician approval), may there-
fore demonstrate greater efficacy for the improvement of
adherence outcomes, as demonstrated by Wilson et al. In
this regard, interventions that emphasize shared decision-
making and the use of motivational interviewing tech-
niques,47,55 which are designed to increase intrinsic moti-
vation and foster self-efficacy, may show the most promise
for the improvement of ICS adherence.
Limitations and strengths of the present review
First, this review may be criticized for the small number of
studies included, particularly those that were adequately
powered. A related limitation is the small number of CCM
component combinations tested, which limits our ability to
determine which one(s) was (were) most critical to success.
However, the two trials that included the most (i.e., four)
CCM components demonstrated the most significant effects
on improving ICS adherence, suggesting the efficacy of
intervening within the CCM framework. Moreover, our
findings are well supported by prior meta-analyses28,30
addressing the suitability of CCM implementation tooptimize health benefits in patients with various chronic
diseases including diabetes, congestive heart failure, COPD
and depression. Second, the restriction for English language
studies may have introduced a selection bias. However,
during a period where redundant publication is common
practice, the likelihood that important studies would be
unpublished in English is low. Third, we did not assess the
presence of publication bias, though the presence of
negative studies makes this bias less likely. Fourth, the
interventions provided in the studies reviewed were not
always well described. Therefore, inaccurate assignment of
CCM components to these studies may have been
committed. Finally, we did not have access to data that
would have allowed us to assess the optimal dose of CCM
components in the study interventions. It is possible that
the interventions we studied had positive effects because
doing trials requires energy and commitment to participate
in the intervention.28 This commitment on the part of
participants may be the active ingredient of initial success,
but this is difficult to estimate. Simplified comparisons
based solely on the presence or absence of CCM compo-
nents may mask important differences between studies.28
Further research is needed to refine the understanding of
mechanisms explaining the beneficial effects of multi-level
programs.
Despite the above limitations, this review also has
a number of important strengths. First, to our knowledge,
this is the first systematic review to specifically examine the
efficacy of interventions designed to (directly or indirectly)
improve ICS adherence among adult asthmatics. Second, by
conducting a meta-analysis, we were able to objectively
quantify the relative magnitude of the intervention effects
across studies. Finally, presenting pooled effect sizes as
a function of the number of CCM components used across
the studies may be considered a novel and clinically rele-
vant way of summarizing the extant literature, as it provides
support for a doseeresponse relationship between the
number of CCM components and improvements in ICS
adherence among adult asthmatics that provides specific
direction for future intervention work in this area.Conclusions
In conclusion, the inclusion of a greater number of CCM
components within interventions was associated with
greater effects on ICS adherence outcomes. Further, this
review suggests that interventions that include motiva-
tional support (i.e., motivational interviewing) may show
the greatest promise in improving adherence, though
more research is needed to confirm this. Finally, research
is needed in the development process of behavioral
interventions to improve adherence behavior among
asthmatics. Over the last two decades, several interven-
tional studies have been conducted and published
without any real coherent theoretical of development
framework, and have “leapfrogged” important stages of
development. The challenge for future studies will be to
bridge the gap between basic behavioral/social science
research, behavioural medicine intervention studies
(efficacy trials) and public health/community studies
(effectiveness trials).
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